Catalyst Pharmaceuticals, Inc.
CPRX
Rang în acțiuni
#4162
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Preț acțiune
$31.49
Ultima sincronizare: 2026-07-21
Capitalizare de piață
$3.85B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
49.88%
Țară
US
Tranzacționează Catalyst Pharmaceuticals, Inc. (CPRX)
Categorie
Healthcare
Câștiguri pentru Catalyst Pharmaceuticals, Inc. (CPRX)
Câștiguri în Mar 2026 TTM: $296.46M
Conform celor mai recente rapoarte financiare ale Catalyst Pharmaceuticals, Inc., câștigurile actuale ale companiei sunt $296.46M. În anul 2023, compania a înregistrat un câștig de $94.51M, o scădere comparativ cu câștigului din 2022, care a fost de $104.72M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Catalyst Pharmaceuticals, Inc. din 2002 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $296.46M | 37.08% |
| 2024 | $216.26M | 128.82% |
| 2023 | $94.51M | -9.75% |
| 2022 | $104.72M | 98.83% |
| 2021 | $52.67M | 25.73% |
| 2020 | $41.89M | 25.39% |
| 2019 | $33.41M | -198.25% |
| 2018 | $-34.00M | 84.68% |
| 2017 | $-18.41M | 1.88% |
| 2016 | $-18.07M | -10.68% |
| 2015 | $-20.23M | 30.46% |
| 2014 | $-15.51M | 27.60% |
| 2013 | $-12.15M | 198.17% |
| 2012 | $-4.08M | -36.22% |
| 2011 | $-6.39M | 59.52% |
| 2010 | $-4.01M | -44.68% |
| 2009 | $-7.24M | -31.45% |
| 2008 | $-10.56M | 155.21% |
| 2007 | $-4.14M | 51.66% |
| 2006 | $-2.73M | 51.18% |
| 2005 | $-1.81M | 234.44% |
| 2004 | $-539.82K | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-255.95K | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $5.27B | 1,679.31% |
US
|
|
| $-3.09B | -1,141.29% |
US
|
|
| $-4.02B | -1,454.73% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 557.99% |
NL
|
